Market Notice150/19 – Information regarding the rights issue from Follicum AB

The last day of trading in the company’s shares FOLLI including the right to receive subscription rights is June 13, 2019. The first day excluding the right to obtain the rights is June 14, 2019.

One (1) share entitles the owner to one (1) subscription right. Three (3) subscription rights entitle the owner to subscribe for one (1) new share, at the price of SEK 2.20 (1:3 á SEK 2.20).  

Trading with subscription rights will take place from June 20, 2019 until July 2, 2019 on Spotlight Stock Market.

Trading with the paid subscribed shares will take place from June 20, 2019 until the registration of the issue at Bolagsverket.  

The subscription period lasts from June 20, 2019 to July 4, 2019.

Information about the subscription right:

Shortname: FOLLI TR
ISIN-code: SE0012740249
Orderbook-ID: 592V
CFI: RSSXXR
FISN: FOLLICUMAB/SUBS RTS NL PD
First day of trading: June 20, 2019
Last day of trading: July 2, 2019
Market Segment: SPSE
MIC Code: XSAT
Tick table/liquidity band #: A (Other instruments) 

Information about the paid subscribed share:

Shortname: FOLLI BTA
ISIN-code: SE0012740256
Orderbook-ID: 592U
CFI: ESNUFR
FISN: FOLLICUMAB/SH
Trading period: June 20, 2019 until the registration of the issue at Bolagsverket.
Market Segment: SPSE
MIC Code: XSAT
Tick table/liquidity band #: A (Other instruments) 

Please be advised that if the rights issue give rise to a conversion factor, all overnight orders in the company’s orderbook will be deleted. If so this will occur after closing on June 13, 2019. 

Stockholm June 11, 2019

Spotlight Stock Market
08-511 68 000
info@spotlightstockmarket.com 

Om oss

Follicum AB (Spotlight: FOLLI) utvecklar läkemedel baserade på vävnadsreparerande peptider med potentiell användning inom en rad sjukdomsområden. Bolagets längst framskridna läkemedelskandidat, FOL-005 mot håravfall, utvärderas för närvarande i en fas 2a-studie i samarbete med internationellt välrenommerade specialistkliniker. Inom diabetesområdet drivs ett projekt som syftar till att skydda insulinproducerande celler mot skador och därmed minska risken för komplikationer. Baserat på lovande prekliniska resultat pågår förberedelser inför en fas 1-studie, vilken förväntas starta under 2021. Båda projekten har potential att bli så kallade first-in-class-läkemedel. För mer information, besök www.follicum.com.

Prenumerera

Dokument & länkar